Medicine at Mount Sinai to cover systems pharmacology. I wish to thank the entire Editorial Team for their enthusiasm and active participation in the journal.
One of my primary goals is to increase articles from outside the United States and Europe. Indeed, of the 97 publications in 2017, 90% came from the United States or Europe (54% and 36%, respectively). We will actively reach out to PMX groups from several areas of the world and invite them to submit perspectives, editorials, and original research articles, as publication fees may be reduced or waived for articles from developing countries. 3 Recently, PSP published a report 4 of the first congress from the Iberoamerican Pharmacometrics Network, which was founded in 2017 as the association of research groups from Argentina, Brazil, Chile, Colombia, Cuba, Mexico, Panama, Spain, and Uruguay and is interested in the promotion and advancement of pharmacometrics in Latin America. PSP will also encourage submissions from and be more visible at the Word Conference on Pharmacometrics, 5 the next meeting of which is to be held in 2020 in Cape Town, South Africa.
A second goal is to welcome more articles and tutorials on methods and software tools in PMX and QSP, so the journal will be a natural reference for new (and existing) members of our ever-growing community. In February 2019, a new virtual issue "Methods and Software Tools" was launched and already has 113 articles. The authors of main software used in the field have been invited to write tutorials, and many have agreed. We will also reach the Statistics and Pharmacometrics Special Interest Group (SxP SIG) of both the American Statistical Association and the International Society of Pharmacometrics, 6 created in 2016, to increase publications and tutorials in that area.
Given the growing importance of model-informed drug discovery and development (MIDD), the new virtual issue "Regulatory MIDD" was launched with 17 publications. Notably, it includes an article from the Office of Biostatistics and Clinical Pharmacology, Center for Drug Evaluation, of the China National Medical Products Administration 7 as well as articles from the European Medicines Agency, the US Food and Drug Administration, and Japan's Pharmaceuticals and Medical Devices Agency.
In addition to the two recently launched virtual issues noted previously, the Editorial Team also decided to soon launch additional virtual issues on the following topics: biomedical informatics, statistics and pmx, and pregnancy.
Increasing the reproducibility of science [8] [9] [10] is a global goal of scientists of this century, and PSP should participate in that movement. We will work toward enhancing and promoting the use of model repositories for all published articles, as keeping control files in supplementary material does not allow complete reproducibility. The Drug Disease Model Resources (DDMoRe) model repository could be one such option.
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To conclude, I will do my best, with the always supportive help of the Editorial Team and the journal staff, to develop and expand the journal, keeping in mind the scientific quality and spirit that Dr van der Graaf created as the first EIC. PSP should become the reference journal for PMX, QSP, and MIDD to publish our best work and cutting-edge science in those fields. In doing so, we should always keep in mind the vision of Lew Sheiner: better use of quantitative approaches and models, for better development and use of drugs, to treat patients all over the world. Conflict of Interest. The author declared no competing interests for this work.
